The health economics team at the University of Glasgow have developed a comprehensive protocol, outlining the economic analysis of the PATHway project. University of Glasgow will combine and evaluate health outcomes and resource use consequences of the PATHway intervention to determine incremental cost-effectiveness of PATHway compared with usual care. The within trial analysis will focus on the trial period of 6 months and an extrapolation of trial results will allow the team to determine life time costs and outcomes and long-term cost-effectiveness beyond the trial period. The healthcare resource use associated with the PATHway system and the comparator ‘usual care’ will be identified and quantified. Resource utilization will include the cost of delivering the programme (either PATHway or usual care, as intervention cost), the health service costs (healthcare costs), the costs falling on the participants (direct non-medical costs) and the productivity effects in terms of patients’ employment (lost productivity). Health-related outcome measures include physical activity and quality of life (EQ-5D-5L). The EQ-5D is a well-known and widely used generic preference-based measure of health-related quality of life and used to generate a quality-adjusted measure of life expectancy (QALY). The conceptual model below outlines the causal links for the PATHway intervention. Differently coloured arrows indicate whether estimates will be available from trial data or whether these will be informed by the literature. A low number of clinical events is anticipated to be observed during the trial period so that parameter estimates will need to be obtained from the epidemiological literature that links changes in exercise capacity with the probability of experiencing adverse clinical events. Linking changes in exercise capacity and risk profiles to recurrent cardiovascular disease (CVD) events and CVD mortality, the team will estimate the cost per QALY associated with PATHway and will identify whether the costs related to PATHway are offset by a reduction in clinical events and related hospitalisations in the long term.